Menu
Back to User profile » Dr Mehmet Kalender
Papers published by Dr Mehmet Kalender:
Polymorphisms in the MTHFR gene are associated with recurrence risk in lymph node-positive breast cancer patients
Suner A, Buyukhatipoglu H, Aktas G, Kus T, Ulaslı M, Oztuzcu S, Kalender ME, Sevinc A, Kul S, Camci C
OncoTargets and Therapy 2016, 9:5603-5609
Published Date: 9 September 2016
Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel
Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S, Sevinc A, Kul S, Camci C
OncoTargets and Therapy 2016, 9:5073-5080
Published Date: 12 August 2016
Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study
Aktas G, Kus T, Kalender ME, Sevinc A, Camci C, Kul S
OncoTargets and Therapy 2016, 9:1921-1926
Published Date: 1 April 2016
Prognostic impact of initial maximum standardized uptake value of 18F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib
Kus T, Aktas G, Sevinc A, Kalender ME, Yilmaz M, Kul S, Oztuzcu S, Oktay C, Camci C
OncoTargets and Therapy 2015, 8:3749-3756
Published Date: 15 December 2015
Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?
Kus T, Aktas G, Sevinc A, Kalender ME, Camci C
OncoTargets and Therapy 2015, 8:1341-1343
Published Date: 5 June 2015